183616-18-4

Usage

Uses

Used in Organic Synthesis:
3-(Hydroxymethyl)cyclobutan-1-one is used as a key building block for the synthesis of a wide range of organic compounds. Its unique structure allows for the creation of various derivatives and analogs, contributing to the advancement of chemical research and development.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 3-(Hydroxymethyl)cyclobutan-1-one is utilized as a starting material for the development of new drug candidates. Its potential applications in medicine are currently being explored, with a focus on leveraging its chemical properties to address unmet medical needs.
Used in Chemical Research:
3-(Hydroxymethyl)cyclobutan-1-one serves as an important intermediate in chemical research, enabling scientists to investigate its reactivity and properties. This research can lead to the discovery of new reactions and the development of innovative synthetic methods, further expanding the horizons of chemical science.

InChI:InChI=1/C5H8O2/c6-3-4-1-5(7)2-4/h4,6H,1-3H2

Upstream product

• 64-18-6 formic acid 
• 30830-27-4 3-benzyloxy cyclobutanone 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 1081559-36-5 3-benzoyloxycyclobutanone 
• 545882-60-8 (5,8-dioxaspiro[3.4]octan-2-yl)methanol 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 
• 172324-67-3 3-benzyloxymethyl-cyclobutanone 

Downstream Products

• 890529-41-6 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutan-1-one 
• 939775-62-9 3-((tert-butyldimethylsilyl)oxy)methylcyclobutan-1-one 
• 36679-81-9 4-hydroxymethyl-1,2,3,4-tetrahydrofuran-2-one 

Relevant academic research and scientific papers

Synthesis of fluorocyclobutanones and their use in the synthesis of fluoronucleosides

Fluorocyclobutanones can be prepared from reaction of hydroxycyclobutanones with diethylaminosulfur trifluoride (DAST). Other fluorine containing cyclobutanones can be prepared by alkene/fluoroketene cycloadditions. The photochemical ring-opening of these synthetic intermediates with 6-chloropurine produces fluorinated nucleoside analogs.

Synthesis of cyclobutane nucleoside analogues 3: Preparation of carbocyclic derivatives of oxetanocin

A synthesis of cyclobutene nucleoside analogs in which the nucleobase is tethered by a methylene group is described. The coupling of 6-chloropurine with 3-hydroxymethyl-cyclobutanone proceeds via its triflate to give both N-7 and N-9 regioisomers with relative yields corresponding to the calculated charge distribution of the 6-chloropurinyl anion. The stereoselective reduction of the N-alkylated ketones yielded quantitatively one stereoisomer in each case. The structural assignments were based on spectroscopic data and single crystal X-ray diffraction. Attempts to photoexcite the N-7 and N-9 ketones in order to promote ring-expansion did not ensue. Preliminary evidence suggests a photodecarbonylation to cyclopropanes took place.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to the pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious disease, disorders, or conditions in which protein kinase activity is implicated. More particularly, the present invention relates to a compound of Formula I.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

PYRAZOLOTHIAZOLE COMPOUND

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group

2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION

Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular